Novo Nordisk A/S (NVO)

NYQ – Real Time Price. Currency in USD

46.38

-0.79 (-1.66%)

At close: Aug 12, 2026, 3:59 PM EDT

46.28

-0.10 (-0.23%)

After-hours: Aug 12, 2026, 4:18 PM EDT

12.08.2026

Novo Nordisk CEO sees ‘long runway' for weight-loss drugs as obesity grips America

Novo Nordisk CEO argues weight loss drugs could slash health care costs and boost productivity as GLP-1 adoption remains in its early innings.

12.08.2026

Novo Nordisk Dips 4% in a Month: How Should Investors Play the Stock?

NVO faces near-term pressure from flat Wegovy sales, pricing challenges and pipeline setbacks, but its broad cardiometabolic pipeline offers long-term potential.

12.08.2026

PHARMA BETS: CEO turns to AI for next-generation drugs

Novo Nordisk President and CEO Mike Doustdar discusses the company's collaboration with artificial intelligence to accelerate drug discovery and development.

12.08.2026

The Market Is (Still) Underestimating Novo Nordisk

Novo Nordisk remains a Buy, underpinned by strong long-term fundamentals and a promising lead in obesity care, especially with the Wegovy pill. Despite near-term challenges—declining gross margins, high CapEx, and a failed ziltivekimab trial—Novo Nordisk's operating margins and capital allocation remain robust. Management raised 2026 guidance, now expecting adjusted sales and operating profit to decline up to 6%, a significant improvement from prior outlooks.

12.08.2026

Novo Nordisk Stock: Buy or Sell?

Novo Nordisk (NVO -1.17%) is more than just a weight loss company.

12.08.2026

Better Buy: Eli Lilly vs. Novo Nordisk

Eli Lilly has a stronger GLP-1 portfolio and pipeline than Novo Nordisk. Eli Lilly also has a better lineup outside the diabetes and weight-loss areas.

08.08.2026

Novo Nordisk A/S Q2 Earnings Call Highlights

Novo Nordisk A/S NYSE: NVO reported second-quarter adjusted sales growth of 7% at constant exchange rates, supported by GLP-1 volume growth across its obesity and diabetes franchises, while lower realized prices and manufacturing-related costs weighed on margins.

Videos

12.08.2026

Positive

PHARMA BETS: CEO turns to AI for next-generation drugs

05.08.2026

Negative

Novo Nordisk CEO addresses investors' high Wegovy pill expectations

Novo Nordisk A/S (NVO)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Novo Nordisk A/S (NVO)

Novo Nordisk CEO sees ‘long runway' for weight-loss drugs as obesity grips America

Novo Nordisk Dips 4% in a Month: How Should Investors Play the Stock?

PHARMA BETS: CEO turns to AI for next-generation drugs